Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871377 | 0.89 | MEN1 (0.42) | DUTMEN1KMT2A | |
| SCHEMBL1627490 | 0.88 | DUT (0.40) | DUT | |
| SCHEMBL408605 | 0.86 | TAAR1 (0.40) | DUTALDH1A1 | |
| SCHEMBL2696466 | 0.84 | CYP1A2 (0.41) | DUT | |
| SCHEMBL24197444 | 0.82 | TAAR1 (0.44) | KMT2AALDH1A1 | |
| SCHEMBL2142371 | 0.82 | PPARA (0.42) | DUTALDH1A1TSHR | |
| SCHEMBL2821530 | 0.82 | ESR1 (0.45) | MEN1KMT2AALDH1A1 | |
| SCHEMBL2366928 | 0.82 | GFER (0.45) | DUTALDH1A1TSHR | |
| SCHEMBL21178368 | 0.82 | DUT (0.36) | DUT | |
| SCHEMBL1245973 | 0.82 | ELOVL1 (0.41) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497386-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| CN-119161384-A | Estrogen receptor modulating compounds | 雷迪厄斯制药公司 | 2024-12-20 | — | — | CN | disclosed |
| US-20240308986-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. | 2024-09-19 | — | — | US | disclosed |
| CN-112105607-B | Estrogen receptor modulating compounds | 雷迪厄斯制药公司 | 2024-08-27 | — | — | CN | disclosed |
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20220332704-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. | 2022-10-20 | — | — | US | disclosed |
| US-11384068-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2022012622-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |
| EP-3743413-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200347032-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS HEALTH, INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2019144132-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019144132-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| EP-0496548-A1 | Carbacyclin analogs | PURDUE RESEARCH FOUNDATION (US) | 1992-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347032-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | ESR2, GPER1, ESR1 | DUT 4173/4885MEN1 4393/4885KMT2A 3309/4885 |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | DUT 2154/4885MEN1 3601/4885KMT2A 2176/4885 |
| US-20240308986-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | ESR2, GPER1, ESR1 | DUT 4173/4885MEN1 4393/4885KMT2A 3309/4885 |
| US-20220332704-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | ESR2, GPER1, ESR1 | DUT 4173/4885MEN1 4393/4885KMT2A 3309/4885 |
| US-11384068-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | DUT 4173/4885MEN1 4393/4885KMT2A 3309/4885 |
| US-12018019-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | DUT 4173/4885MEN1 4393/4885KMT2A 3309/4885 |
| US-12497386-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | DUT 4173/4885MEN1 4393/4885KMT2A 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.